INT82611

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1999
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 30
Total Number 31
Disease Relevance 20.16
Pain Relevance 5.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (SRC) cytoplasm (SRC) cytosol (SRC)
signal transduction (SRC) cell adhesion (SRC) nucleus (SRC)
Anatomy Link Frequency
neck 1
plasma 1
endothelial cell 1
monocyte 1
skin 1
SRC (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 11 99.92 Very High Very High Very High
peripheral neuropathy 3 99.76 Very High Very High Very High
qutenza 2 98.78 Very High Very High Very High
antagonist 80 97.06 Very High Very High Very High
opiate 45 96.84 Very High Very High Very High
cytokine 12 96.80 Very High Very High Very High
Morphine 15 96.72 Very High Very High Very High
headache 11 93.68 High High
cINOD 10 93.12 High High
Migraine 5 92.52 High High
Disease Link Frequency Relevance Heat
Dermatitis 1 99.92 Very High Very High Very High
Peripheral Neuropathy 3 99.76 Very High Very High Very High
Hypercalcemia 22 99.34 Very High Very High Very High
Adhesions 23 99.30 Very High Very High Very High
Solid Tumor 42 99.00 Very High Very High Very High
Carcinoma 198 98.96 Very High Very High Very High
Ovarian Cancer 300 98.88 Very High Very High Very High
Fatigue 33 98.72 Very High Very High Very High
Head & Neck Cancer 14 98.64 Very High Very High Very High
Hypoxia 13 98.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Inhibition of c-Src and Janus kinase 2 and 3 activities abolished STAT3 activation induced by Galpha14QL, but no physical association between Galpha14QL and c-Src could be detected by coimmunoprecipitation.
Negative_regulation (Inhibition) of c-Src
1) Confidence 0.57 Published 2004 Journal Mol. Pharmacol. Section Abstract Doc Link 15155836 Disease Relevance 0.08 Pain Relevance 0.27
Capsiate inhibits ultraviolet B-induced skin inflammation by inhibiting Src family kinases and epidermal growth factor receptor signaling.
Negative_regulation (inhibiting) of Src in skin associated with qutenza, inflammation and dermatitis
2) Confidence 0.42 Published 2010 Journal Free Radic. Biol. Med. Section Title Doc Link 20123015 Disease Relevance 0.19 Pain Relevance 0.44
To illustrate the role and challenges of these potential biomarkers and endpoints in drug development, we discuss a class of novel molecularly targeted agents, the src kinase inhibitors.
Negative_regulation (inhibitors) of src
3) Confidence 0.42 Published 2009 Journal Oncologist Section Abstract Doc Link 19684076 Disease Relevance 0.73 Pain Relevance 0.09
Increased phosphorylation at both sites was attenuated by pharmacological inhibition of Syk using two different Syk inhibitors, piceatannol and 3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide (OXSI-2), and by inhibition of upstream Src-family kinases (SFKs).
Negative_regulation (inhibition) of Src
4) Confidence 0.42 Published 2008 Journal Am. J. Physiol., Cell Physiol. Section Abstract Doc Link 18715989 Disease Relevance 0.78 Pain Relevance 0.07
Owing to the inactivation of c-Src via CagA interaction, vinculin is dephosphorylated at tyrosine residues, 100 and 1065, by corresponding phosphatases.
Negative_regulation (inactivation) of c-Src
5) Confidence 0.42 Published 2007 Journal Cell. Microbiol. Section Abstract Doc Link 17217431 Disease Relevance 0.97 Pain Relevance 0.09
We have found that the inhibition of src-related nonreceptor tyrosine kinases blocks forskolin-induced proenkephalin gene expression without having any effect on serine-133-phosphorylated CREB levels and that constitutively activated src kinase can activate the proenkephalin promoter.
Negative_regulation (inhibition) of src
6) Confidence 0.41 Published 1999 Journal J. Neurochem. Section Abstract Doc Link 10386963 Disease Relevance 0 Pain Relevance 0.03
The indomethacin-induced inhibition of C6 cells proliferation was abrogated by the use of the c-Src inhibitor, PP2 and the MEK inhibitor, PD 098059, suggesting COX-independent mechanisms.
Negative_regulation (inhibitor) of c-Src
7) Confidence 0.41 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16487511 Disease Relevance 0.75 Pain Relevance 0.74
We found that DPDPE-triggered monocyte adhesion requires PI3Kgamma activation and involves Src kinases, the guanine nucleotide exchange factor Vav-1, and the small GTPase Rac1.
Negative_regulation (involves) of Src in monocyte associated with adhesions
8) Confidence 0.41 Published 2006 Journal J. Immunol. Section Abstract Doc Link 16424197 Disease Relevance 0.61 Pain Relevance 0.48
We and others have previously reported that inhibition of Src protects from EC barrier disruption and angiogenesis [6,8,10].
Negative_regulation (inhibition) of Src
9) Confidence 0.40 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0 Pain Relevance 0
During the course of these investigations, we also noted an effect of the peripheral opiate antagonist methylnaltrexone (MNTX) on endothelial cell migration and proliferation that occurred beyond the VEGF receptor, through a mechanism that involves inhibition of Src and Akt.
Negative_regulation (inhibition) of Src in endothelial cell associated with antagonist and opiate
10) Confidence 0.40 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.92 Pain Relevance 0.36
Dasatinib, a potent inhibitor of src family kinases, inhibits migration and invasion of mesothelioma in preclinical models [47].
Negative_regulation (inhibitor) of src associated with mesothelioma
11) Confidence 0.35 Published 2008 Journal Curr Treat Options Oncol Section Body Doc Link PMC2782121 Disease Relevance 0.58 Pain Relevance 0.05
Furthermore, we found that an Src kinase was involved in STAT6 activation because 1) Src kinase activity was induced by IL-4, 2) Src kinase activity, but not Janus kinase, was inhibited by salicylates in vitro, 3) cells expressing viral Src had constitutive STAT6 phosphorylation, and 4) cells lacking Src showed low STAT6 phosphorylation in response to IL-4.
Negative_regulation (lacking) of Src
12) Confidence 0.35 Published 2002 Journal J. Immunol. Section Abstract Doc Link 11801685 Disease Relevance 0.48 Pain Relevance 0.25
Furthermore, we found that an Src kinase was involved in STAT6 activation because 1) Src kinase activity was induced by IL-4, 2) Src kinase activity, but not Janus kinase, was inhibited by salicylates in vitro, 3) cells expressing viral Src had constitutive STAT6 phosphorylation, and 4) cells lacking Src showed low STAT6 phosphorylation in response to IL-4.
Negative_regulation (inhibited) of Src
13) Confidence 0.35 Published 2002 Journal J. Immunol. Section Abstract Doc Link 11801685 Disease Relevance 0.65 Pain Relevance 0.26
The plasma concentrations of morphine and MNTX in patients after parenteral or oral administration are consistent with the levels that regulated synergistic inhibition of VEGF-induced angiogenesis and inhibited Src in our in vitro model (IC50 = ~10 nM) [10].
Negative_regulation (inhibited) of Src in plasma associated with morphine
14) Confidence 0.29 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.25 Pain Relevance 1.13
We are currently examining the role of these tyrosine phosphatases in MNTX inhibition of VEGF-induced Src activation and angiogenesis.
Spec (examining) Negative_regulation (inhibition) of Src
15) Confidence 0.29 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.27 Pain Relevance 0
This study extends these finding by demonstrating that the potent protein tyrosine phosphatase inhibitor, 3,4-Dephostatin, blocks MNTX inhibition of VEGF-induced Src and Akt phosphorylation. 3,4-Dephostatin is known to block the phosphatase activity of PTP-1B, SHPTP-1 and CD45 [20,40,46-48].
Negative_regulation (inhibition) of Src
16) Confidence 0.29 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2831839 Disease Relevance 0.20 Pain Relevance 0
The Src family of kinases has been implicated in the pathogenesis of head and neck cancer.95,96 In addition, Grandis and colleagues have shown that combined inhibition of the Src and EGFR kinases inhibits HNSCC cell growth and invasion.97 Currently, there is an ongoing phase I study to test the safety of cetuximab and the Src inhibitor dasatinib in patients with advanced malignancies, which will provide more clinical data with regards to the safety of this combination.
Negative_regulation (inhibition) of Src in neck associated with head & neck cancer
17) Confidence 0.24 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2921255 Disease Relevance 0.53 Pain Relevance 0
Dasatinib is a potent inhibitor of multiple oncogenic kinases including Src, cKIT, BCR-ABL, PDGFR, and ephrin A.
Negative_regulation (inhibitor) of Src
18) Confidence 0.23 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2868849 Disease Relevance 0.64 Pain Relevance 0
In these experiments inhibition of Src kinases in originally cetuximab-resistant cell lines resulted in a regaining of sensitivity against cetuximab, indicating a close interaction between Src and EGF-R regarding the processes causing cetuximab resistance in tumour cells [27].
Negative_regulation (inhibition) of Src associated with cancer
19) Confidence 0.23 Published 2010 Journal Head Neck Oncol Section Body Doc Link PMC2868849 Disease Relevance 0.65 Pain Relevance 0
No sensitizing effect of Mcl-1 knockdown in HCC cells was observed for the treatment with JNK1 and Src kinase inhibitors.
Negative_regulation (inhibitors) of Src associated with carcinoma
20) Confidence 0.21 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.31 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox